Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has become the most important drug-resistant microbial pathogen in countries throughout the world. Morbidity and mortality due to MRSA infections continue to increase despite efforts to improve infection control measures and to develop new antibiotics. Therefore alternative antimicrobial strategies that do not give rise to development of resistance are urgently required. A group of therapeutic interventions has been developed in the field of photomedicine with the common theme that they rely on electromagnetic radiation with wavelengths between 200 and 1000 nm broadly called “light”. These techniques all use simple absorption of photons by specific chromophores to deliver the killing blow to microbial cells while leaving the surrounding host mammalian cells relatively unharmed. Photodynamic inactivation uses dyes called photosensitizers (PS) that bind specifically to MRSA cells and not host cells, and generate reactive oxygen species including singlet oxygen and singlet oxygen upon illumination. Sophisticated molecular strategies to target the PS to MRSA cells have been designed. Ultraviolet C radiation can damage microbial DNA without unduly harming host DNA. Blue light can excite endogenous porphyrins and flavins in MRSA cells that are not present in host cells. Near-infrared lasers can interfere with microbial membrane potentials without raising the temperature of the tissue. Taken together these innovative approaches towards harnessing the power of light suggest that the ongoing threat of MRSA may eventually be defeated.
Keywords: Photodynamic therapy, MRSA, PDI, blue light, UV light, photosensitizer, multi-drug efflux pump.
Current Pharmaceutical Design
Title:Harnessing the Power of Light to Treat Staphylococcal Infections Focusing on MRSA
Volume: 21 Issue: 16
Author(s): Tanupriya Agrawal, Pinar Avci, Gaurav K. Gupta, Ardeshir Rineh, Shanmugamurthy Lakshmanan, Vincent Batwala, George P Tegos and Michael R. Hamblin
Affiliation:
Keywords: Photodynamic therapy, MRSA, PDI, blue light, UV light, photosensitizer, multi-drug efflux pump.
Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) has become the most important drug-resistant microbial pathogen in countries throughout the world. Morbidity and mortality due to MRSA infections continue to increase despite efforts to improve infection control measures and to develop new antibiotics. Therefore alternative antimicrobial strategies that do not give rise to development of resistance are urgently required. A group of therapeutic interventions has been developed in the field of photomedicine with the common theme that they rely on electromagnetic radiation with wavelengths between 200 and 1000 nm broadly called “light”. These techniques all use simple absorption of photons by specific chromophores to deliver the killing blow to microbial cells while leaving the surrounding host mammalian cells relatively unharmed. Photodynamic inactivation uses dyes called photosensitizers (PS) that bind specifically to MRSA cells and not host cells, and generate reactive oxygen species including singlet oxygen and singlet oxygen upon illumination. Sophisticated molecular strategies to target the PS to MRSA cells have been designed. Ultraviolet C radiation can damage microbial DNA without unduly harming host DNA. Blue light can excite endogenous porphyrins and flavins in MRSA cells that are not present in host cells. Near-infrared lasers can interfere with microbial membrane potentials without raising the temperature of the tissue. Taken together these innovative approaches towards harnessing the power of light suggest that the ongoing threat of MRSA may eventually be defeated.
Export Options
About this article
Cite this article as:
Agrawal Tanupriya, Avci Pinar, Gupta K. Gaurav, Rineh Ardeshir, Lakshmanan Shanmugamurthy, Batwala Vincent, Tegos P George and Hamblin R. Michael, Harnessing the Power of Light to Treat Staphylococcal Infections Focusing on MRSA, Current Pharmaceutical Design 2015; 21 (16) . https://dx.doi.org/10.2174/1381612821666150310102318
DOI https://dx.doi.org/10.2174/1381612821666150310102318 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation
Current Drug Targets Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies
Current Drug Delivery Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Analogue of Melanotan II (MTII): A Novel Melanotropin with Superpotent Action on Frog Skin
Protein & Peptide Letters Actinic Keratosis: Review of the Literature and New Patents
Recent Patents on Inflammation & Allergy Drug Discovery Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Multimerization Improves Targeting of Peptide Radio-Pharmaceuticals
Current Pharmaceutical Design Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Nitric Oxide-NASIDS Donor Prodrugs as Hybrid Safe Anti-inflammatory Agents
Current Topics in Medicinal Chemistry Modulation Effects of Piracetam and Ginkgo biloba on the Cognitive and Working Memory Functions: Psychometric Study
Current Psychopharmacology Naturally Occurring NF-κB Inhibitors
Mini-Reviews in Medicinal Chemistry The Emerging Role of Nitrite as an Endogenous Modulator and Therapeutic Agent of Cardiovascular Function
Current Medicinal Chemistry Topical Dermatological Drug Delivery: Quo Vadis?
Current Drug Delivery Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs)
Current Topics in Medicinal Chemistry Pharmacological Suppression of Premature Stop Mutations that Cause Genetic Diseases
Current Pharmacogenomics Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Matrix Metalloproteinase Inhibitors as Prospective Agents for the Prevention and Treatment of Cardiovascular and Neoplastic Diseases
Current Topics in Medicinal Chemistry Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes
Current Stem Cell Research & Therapy